{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:06:15Z","timestamp":1790759175480,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001826","name":"zonmw","doi-asserted-by":"publisher","award":["848016010"],"award-info":[{"award-number":["848016010"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40264-021-01135-2","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T07:02:27Z","timestamp":1636182147000},"page":"1271-1281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1991-0552","authenticated-orcid":false,"given":"Nikki","family":"de Rouw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berber","family":"Piet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hieronymus J.","family":"Derijks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"issue":"Suppl. 5","key":"1135_CR1","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v31\u20139.","journal-title":"Ann Oncol"},{"issue":"Suppl. 5","key":"1135_CR2","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, Committee EG. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v40-55.","journal-title":"Ann Oncol"},{"issue":"Suppl. 4","key":"1135_CR3","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192-237.","journal-title":"Ann Oncol"},{"key":"1135_CR4","unstructured":"European Medicines Agency (EMA). ALIMTA EPAR: product information. 2017. Eli Lilly, Utrecht, Netherlands"},{"issue":"7","key":"1135_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/JTO.0000000000000207","volume":"9","author":"C Gridelli","year":"2014","unstructured":"Gridelli C, de Marinis F, Thomas M, Prabhash K, El Kouri C, Blackhall F, et al. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. J Thorac Oncol. 2014;9(7):991\u20137.","journal-title":"J Thorac Oncol"},{"key":"1135_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","volume":"146","author":"N de Rouw","year":"2020","unstructured":"de Rouw N, Boosman RJ, van de Bruinhorst H, Biesma B, van den Heuvel MM, Burger DM, et al. Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer. 2020;146:30\u20135.","journal-title":"Lung Cancer"},{"issue":"5","key":"1135_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40262-020-00972-1","volume":"60","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Boosman RJ, Huitema ADR, Hilbrands LB, Svensson EM, Derijks HJ, et al. Rethinking the application of pemetrexed for patients with renal impairment: a pharmacokinetic analysis. Clin Pharmacokinet. 2021;60(5):649\u201354.","journal-title":"Clin Pharmacokinet"},{"key":"1135_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2019.08.012","volume":"121","author":"S Visser","year":"2019","unstructured":"Visser S, Koolen SLW, de Bruijn P, Belderbos HNA, Cornelissen R, Mathijssen RHJ, et al. Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: a prospective cohort study. Eur J Cancer. 2019;121:64\u201373.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1135_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol. 2006;57(4):401\u201311.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"1135_CR10","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","volume":"31","author":"LG Paz-Ares","year":"2013","unstructured":"Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895\u2013902.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1135_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375\u201391.","journal-title":"Ann Oncol"},{"issue":"22","key":"1135_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"2","key":"1135_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 Study. J Clin Oncol. 2020;38(2):115\u201323.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1135_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.hoc.2012.02.002","volume":"26","author":"M Visentin","year":"2012","unstructured":"Visentin M, Zhao R, Goldman ID. The antifolates. Hematol Oncol Clin N Am. 2012;26(3):629\u201348, ix.","journal-title":"Hematol Oncol Clin N Am."},{"key":"1135_CR15","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.1046\/j.1523-1755.2001.59780221.x","volume":"78","author":"B Fowler","year":"2001","unstructured":"Fowler B. The folate cycle and disease in humans. Kidney Int Suppl. 2001;78:S221\u20139.","journal-title":"Kidney Int Suppl"},{"key":"1135_CR16","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1016\/S0021-9258(18)64576-4","volume":"235","author":"SF Zakrzewski","year":"1960","unstructured":"Zakrzewski SF, Nichol CA. Evidence for a single enzyme reducing folate and dihydrofolate. J Biol Chem. 1960;235:2984\u20138.","journal-title":"J Biol Chem"},{"key":"1135_CR17","volume-title":"Antifolate drugs in cancer therapy","author":"RL Kisliuk","year":"1999","unstructured":"Kisliuk RL. Folate biochemistry in relation to antifolate selectivity. In: Javckman AL, editor. Antifolate drugs in cancer therapy. New York: Humana Press Inc.; 1999."},{"issue":"3","key":"1135_CR18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1124\/mol.108.045443","volume":"74","author":"R Zhao","year":"2008","unstructured":"Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID. The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol. 2008;74(3):854\u201362.","journal-title":"Mol Pharmacol"},{"issue":"2 Suppl. 6","key":"1135_CR19","first-page":"42","volume":"26","author":"LG Mendelsohn","year":"1999","unstructured":"Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol. 1999;26(2 Suppl. 6):42\u20137.","journal-title":"Semin Oncol"},{"issue":"6","key":"1135_CR20","first-page":"1116","volume":"57","author":"C Shih","year":"1997","unstructured":"Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57(6):1116\u201323.","journal-title":"Cancer Res"},{"issue":"13","key":"1135_CR21","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1158\/0008-5472.CAN-08-4979","volume":"69","author":"AC Racanelli","year":"2009","unstructured":"Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009;69(13):5467\u201374.","journal-title":"Cancer Res"},{"issue":"1","key":"1135_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","volume":"41","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41(1):36\u201351.","journal-title":"Cancer"},{"issue":"2","key":"1135_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","volume":"6","author":"S Chattopadhyay","year":"2007","unstructured":"Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007;6(2):404\u201317.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1135_CR24","first-page":"1087","volume":"43","author":"DW Fry","year":"1983","unstructured":"Fry DW, Anderson LA, Borst M, Goldman ID. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res. 1983;43(3):1087\u201392.","journal-title":"Cancer Res"},{"key":"1135_CR25","unstructured":"National Centre for Biotechnology Information. PubChem compound summary for CID 135410875, pemetrexed. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Pemetrexed. Accessed 28 Oct 2021."},{"issue":"11","key":"1135_CR26","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1200\/JCO.1995.13.11.2842","volume":"13","author":"DA Rinaldi","year":"1995","unstructured":"Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol. 1995;13(11):2842\u201350.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1135_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44(5):372\u201380.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1135_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","volume":"24","author":"AC Mita","year":"2006","unstructured":"Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24(4):552\u201362.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1135_CR29","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589\u201397.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1135_CR30","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543\u201351.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1135_CR31","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1135_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-005-0035-2","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical application of a semimechanistic-physiologic population PK\/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. 2006;57(4):427\u201335.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1135_CR33","doi-asserted-by":"crossref","unstructured":"Latz J, Adachi S, Symanowski J, et al. Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRs) to clinical study results from Western and Japanese patient populations. In: 12th world conference on lung cancer abstract PD4-3-4. J Thorac Oncol. 2007;2(8):s4.","DOI":"10.1097\/01.JTO.0000283390.06980.49"},{"issue":"6","key":"1135_CR34","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.cllc.2015.01.001","volume":"16","author":"CY Chen","year":"2015","unstructured":"Chen CY, Lin JW, Huang JW, Chen KY, Shih JY, Yu CJ, et al. Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2015;16(6):e131\u201340.","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"1135_CR35","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/ijc.33721","volume":"149","author":"RJ Boosman","year":"2021","unstructured":"Boosman RJ, Dorlo TPC, Rouw N, Burgers JA, Dingemans A-MC, Heuvel MM, et al. Toxicity of pemetrexed during renal impairment explained: implications for safe treatment. Int J Cancer. 2021;149(8):1576\u201384.","journal-title":"Int J Cancer"},{"issue":"11 Pt 1","key":"1135_CR36","first-page":"4441","volume":"41","author":"RG Poser","year":"1981","unstructured":"Poser RG, Sirotnak FM, Chello PL. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo. Cancer Res. 1981;41(11 Pt 1):4441\u20136.","journal-title":"Cancer Res"},{"issue":"12","key":"1135_CR37","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471\u201382.","journal-title":"Oncologist"},{"issue":"4","key":"1135_CR38","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1200\/JCO.1999.17.4.1194","volume":"17","author":"JJ Rusthoven","year":"1999","unstructured":"Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17(4):1194.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1135_CR39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/annonc\/mdf115","volume":"13","author":"SJ Clarke","year":"2002","unstructured":"Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol. 2002;13(5):737\u201341.","journal-title":"Ann Oncol"},{"issue":"7","key":"1135_CR40","first-page":"545","volume":"1","author":"C Niyikiza","year":"2002","unstructured":"Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002;1(7):545\u201352.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1135_CR41","first-page":"908","volume":"39","author":"RG Stoller","year":"1979","unstructured":"Stoller RG, Kaplan HG, Cummings FJ, Calabresi P. A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. Cancer Res. 1979;39(3):908\u201312.","journal-title":"Cancer Res"},{"issue":"2","key":"1135_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228\u201337.","journal-title":"Cancer"},{"issue":"9","key":"1135_CR43","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916\u201324.","journal-title":"Cancer"},{"issue":"23","key":"1135_CR44","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555\u201363.","journal-title":"Cancer"},{"issue":"4","key":"1135_CR45","doi-asserted-by":"publisher","first-page":"1800884","DOI":"10.1183\/13993003.00884-2018","volume":"52","author":"S Visser","year":"2018","unstructured":"Visser S, Huisbrink J, van\u2019t Veer NE, van Toor JJ, van Boxem AJM, van Walree NC, et al. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J. 2018;52(4):1800884.","journal-title":"Eur Respir J"},{"issue":"1","key":"1135_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s41100-020-00292-x","volume":"6","author":"K Umehara","year":"2020","unstructured":"Umehara K, Yama K, Koike N, Takayama S, Wakamoto A, Hatuyama T, et al. Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study. Renal Replace Ther. 2020;6(1):43.","journal-title":"Renal Replace Ther."},{"issue":"10","key":"1135_CR47","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.02780312","volume":"7","author":"MA Perazella","year":"2012","unstructured":"Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7(10):1713\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1135_CR48","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/03007995.2018.1439462","volume":"34","author":"G Middleton","year":"2018","unstructured":"Middleton G, Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, et al. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Curr Med Res Opin. 2018;34(5):865\u201371.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1135_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cllc.2017.04.003","volume":"18","author":"CJ Langer","year":"2017","unstructured":"Langer CJ, Paz-Ares LG, Wozniak AJ, Gridelli C, de Marinis F, Pujol JL, et al. Safety analyses of pemetrexed-cisplatin and pemetrexed maintenance therapies in patients with advanced non-squamous NSCLC: retrospective analyses from 2 phase III studies. Clin Lung Cancer. 2017;18(5):489\u201396.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"1135_CR50","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"L Paz-Ares","year":"2012","unstructured":"Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247\u201355.","journal-title":"Lancet Oncol"},{"key":"1135_CR51","unstructured":"ASCO. Emetic risk charts. https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/advocacy-and-policy\/documents\/2020-Emetic-Risk-Charts.pdf. Accessed 28 Oct 2021."},{"issue":"4","key":"1135_CR52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc1318","volume":"4","author":"ST Sonis","year":"2004","unstructured":"Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277\u201384.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1135_CR53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2174\/157488612805076543","volume":"7","author":"C Pierard-Franchimont","year":"2012","unstructured":"Pierard-Franchimont C, Lesuisse M, Humbert P, Delvenne P, Pierard GE. Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf. 2012;7(5):357\u201360.","journal-title":"Curr Drug Saf"},{"key":"1135_CR54","first-page":"1010","volume":"14","author":"G Eichhoff","year":"2020","unstructured":"Eichhoff G. Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin. Ecancer Med Sci. 2020;14:1010.","journal-title":"Ecancer Med Sci."},{"issue":"5","key":"1135_CR55","first-page":"769","volume":"2","author":"C Pierard-Franchimont","year":"2011","unstructured":"Pierard-Franchimont C, Quatresooz P, Reginster MA, Pierard GE. Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett. 2011;2(5):769\u201372.","journal-title":"Oncol Lett"},{"issue":"5","key":"1135_CR56","first-page":"AB211","volume":"72","author":"C Guitierrez Garcia-Rodrigo","year":"2015","unstructured":"Guitierrez Garcia-Rodrigo C, Menis D, Sanz-Motilva VHL, Larrain H, Ortiz de Frutos J, Vanaclocha SF. Pemetrexed-related cytotoxic skin reaction. J Am Acad Dermatol. 2015;72(5):AB211.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1135_CR57","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1097\/JTO.0b013e31822e722f","volume":"6","author":"B Eguia","year":"2011","unstructured":"Eguia B, Ruppert AM, Fillon J, Lavole A, Gounant V, Epaud C, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol. 2011;6(12):2083\u20139.","journal-title":"J Thorac Oncol"},{"key":"1135_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.lungcan.2017.11.026","volume":"115","author":"L Zhang","year":"2018","unstructured":"Zhang L, Belani CP, Zhang PH, Wang X, Yang L, Orlando M, et al. Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial. Lung Cancer. 2018;115:121\u20136.","journal-title":"Lung Cancer"},{"issue":"9","key":"1135_CR59","first-page":"161","volume":"109","author":"M Horneber","year":"2012","unstructured":"Horneber M, Fischer I, Dimeo F, Ruffer JU, Weis J. Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment. Dtsch Arztebl Int. 2012;109(9):161\u201371 (quiz 72).","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"1135_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.1780330102","volume":"33","author":"SL Morgan","year":"1990","unstructured":"Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33(1):9\u201318.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1135_CR61","first-page":"2331","volume":"56","author":"T Alati","year":"1996","unstructured":"Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, et al. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Cancer Res. 1996;56(10):2331\u20135.","journal-title":"Cancer Res"},{"issue":"2","key":"1135_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s002800050017","volume":"45","author":"JD Roberts","year":"2000","unstructured":"Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, et al. Weekly iometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol. 2000;45(2):103\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5A","key":"1135_CR63","first-page":"3235","volume":"18","author":"JF Worzalla","year":"1998","unstructured":"Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res. 1998;18(5A):3235\u20139.","journal-title":"Anticancer Res"},{"issue":"7","key":"1135_CR64","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0006-2952(01)00532-9","volume":"61","author":"R Zhao","year":"2001","unstructured":"Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol. 2001;61(7):857\u201365.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"1135_CR65","first-page":"3190","volume":"44","author":"I Fabre","year":"1984","unstructured":"Fabre I, Fabre G, Goldman ID. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res. 1984;44(8):3190\u20135.","journal-title":"Cancer Res"},{"issue":"3","key":"1135_CR66","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00280-015-2954-x","volume":"77","author":"Y Takagi","year":"2016","unstructured":"Takagi Y, Hosomi Y, Nagamata M, Watanabe K, Takahashi S, Nakahara Y, et al. Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy. Cancer Chemother Pharmacol. 2016;77(3):559\u201364.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"1135_CR67","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-06-2393","volume":"13","author":"CH Takimoto","year":"2007","unstructured":"Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L, Beeram M, Forouzesh B, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res. 2007;13(9):2675\u201383.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1135_CR68","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/1078-0432.CCR-08-0791","volume":"15","author":"JE Latz","year":"2009","unstructured":"Latz JE, Schneck KL, Nakagawa K, Miller MA, Takimoto CH. Population pharmacokinetic\/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patients. Clin Cancer Res. 2009;15(1):346\u201354.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1135_CR69","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1634\/theoncologist.2014-0221","volume":"19","author":"Y Takagi","year":"2014","unstructured":"Takagi Y, Hosomi Y, Sunami K, Nakahara Y, Okuma Y, Yomota M, et al. A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. Oncologist. 2014;19(11):1194\u20139.","journal-title":"Oncologist"},{"issue":"13","key":"1135_CR70","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/cncr.32028","volume":"125","author":"N Singh","year":"2019","unstructured":"Singh N, Baldi M, Kaur J, Muthu V, Prasad KT, Behera D, et al. Timing of folic acid\/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: the PEMVITASTART randomized trial. Cancer. 2019;125(13):2203\u201312.","journal-title":"Cancer"},{"issue":"6","key":"1135_CR71","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cllc.2018.05.017","volume":"19","author":"Z Schlei","year":"2018","unstructured":"Schlei Z, Tan W, Faber MG, Chen H, Meagher A, Dy GK. Safety of same-day vitamin B12 supplementation in patients receiving pemetrexed for the treatment of non-small-cell lung cancer or pleural mesothelioma: a retrospective analysis. Clin Lung Cancer. 2018;19(6):467\u201375.","journal-title":"Clin Lung Cancer"},{"issue":"11","key":"1135_CR72","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1248\/bpb.b15-00435","volume":"38","author":"T Sakurada","year":"2015","unstructured":"Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Konaka K, Okada N, et al. Pemetrexed-induced rash may be prevented by supplementary corticosteroids. Biol Pharm Bull. 2015;38(11):1752\u20136.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"1135_CR73","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1078155215583523","volume":"22","author":"R Elsoueidi","year":"2016","unstructured":"Elsoueidi R, Lander MJ, Richa EM, Adane ED. Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions. J Oncol Pharm Pract. 2016;22(2):271\u20134.","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl. 5","key":"1135_CR74","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(Suppl. 5):v111\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"1135_CR75","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1135_CR76","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.1987.5.12.2017","volume":"5","author":"SP Ackland","year":"1987","unstructured":"Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987;5(12):2017\u201331.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1135_CR77","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1073\/pnas.95.8.4550","volume":"95","author":"M Chow","year":"1998","unstructured":"Chow M, Rubin H. Selective killing of preneoplastic and neoplastic cells by methotrexate with leucovorin. Proc Natl Acad Sci USA. 1998;95(8):4550\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1135_CR78","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.1985.3.4.485","volume":"3","author":"FM Balis","year":"1985","unstructured":"Balis FM, Savitch JL, Bleyer WA, Reaman GH, Poplack DG. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol. 1985;3(4):485\u20139.","journal-title":"J Clin Oncol"},{"issue":"6 Suppl. 18","key":"1135_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/sonc.2002.37461","volume":"29","author":"ID Goldman","year":"2002","unstructured":"Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol. 2002;29(6 Suppl. 18):3\u201317.","journal-title":"Semin Oncol"},{"issue":"23","key":"1135_CR80","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1021\/jm00101a023","volume":"35","author":"EC Taylor","year":"1992","unstructured":"Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem. 1992;35(23):4450\u20134.","journal-title":"J Med Chem"},{"key":"1135_CR81","unstructured":"Application number 21-462. Pharmacology review Alimta. Center for Drug Evaluation and Research, August 14, 2003."},{"issue":"9","key":"1135_CR82","first-page":"3646","volume":"6","author":"DC Farrugia","year":"2000","unstructured":"Farrugia DC, Aherne GW, Brunton L, Clarke SJ, Jackman AL. Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies. Clin Cancer Res. 2000;6(9):3646\u201356.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1135_CR83","first-page":"605","volume":"4","author":"AC McDonald","year":"1998","unstructured":"McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T, et al. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res. 1998;4(3):605\u201310.","journal-title":"Clin Cancer Res"},{"key":"1135_CR84","first-page":"47","volume":"5","author":"BW McGuire","year":"1987","unstructured":"McGuire BW, Sia LL, Haynes JD, Kisicki JC, Gutierrez ML, Stokstad EL. Absorption kinetics of orally administered leucovorin calcium. NCI Monogr. 1987;5:47\u201356.","journal-title":"NCI Monogr"},{"key":"1135_CR85","unstructured":"OCEBM Levels of Evidence Working Group, \u201cThe Oxford Levels of Evidence 2\u201d. Oxford Centre for Evidence-Based Medicine. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."},{"issue":"6","key":"1135_CR86","first-page":"1602","volume":"37","author":"DS Zaharko","year":"1977","unstructured":"Zaharko DS, Fung WP, Yang KH. Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res. 1977;37(6):1602\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"1135_CR87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/pbc.24770","volume":"61","author":"IJ Cohen","year":"2014","unstructured":"Cohen IJ, Wolff JE. How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity? Pediatr Blood Cancer. 2014;61(1):7\u201310.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"1135_CR88","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2125.1989.tb05429.x","volume":"28","author":"PO Greiner","year":"1989","unstructured":"Greiner PO, Zittoun J, Marquet J, Cheron JM. Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. Br J Clin Pharmacol. 1989;28(3):289\u201395.","journal-title":"Br J Clin Pharmacol"},{"issue":"April","key":"1135_CR89","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.lungcan.2019.01.018","volume":"130","author":"N de Rouw","year":"2019","unstructured":"de Rouw N, Croes S, Posthuma R, Agterhuis DE, Schoenmaekers JJAO, Derijks HJ, et al. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Lung Cancer. 2019;130(April):156\u20138.","journal-title":"Lung Cancer"},{"issue":"3","key":"1135_CR90","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1078-0432.1294.11.3","volume":"11","author":"R Zhao","year":"2005","unstructured":"Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res. 2005;11(3):1294\u2013301.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1135_CR91","first-page":"1857","volume":"37","author":"WD Ensminger","year":"1977","unstructured":"Ensminger WD, Frei E 3rd. The prevention of methotrexate toxicity by thymidine infusions in humans. Cancer Res. 1977;37(6):1857\u201363.","journal-title":"Cancer Res"},{"issue":"6","key":"1135_CR92","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s002800000269","volume":"47","author":"HJ van den Bongard","year":"2001","unstructured":"van den Bongard HJ, Mathjt RA, Boogerd W, Schornagel JH, Soesan M, Schellens JH, et al. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol. 2001;47(6):537\u201340.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"1135_CR93","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1200\/JCO.2003.99.092","volume":"21","author":"M Castro","year":"2003","unstructured":"Castro M. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. J Clin Oncol. 2003;21(21):4066.","journal-title":"J Clin Oncol"},{"key":"1135_CR94","unstructured":"Food and Drug Adminisration (FDA), Voraxaze drug label. 2012. BTG International, Brentwood, TN, United States of America"},{"issue":"5","key":"1135_CR95","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/phar.1360","volume":"34","author":"BC Widemann","year":"2014","unstructured":"Widemann BC, Schwartz S, Jayaprakash N, Christensen R, Pui CH, Chauhan N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy. 2014;34(5):427\u201339.","journal-title":"Pharmacotherapy"},{"issue":"5372","key":"1135_CR96","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/239395b0","volume":"239","author":"BA Chabner","year":"1972","unstructured":"Chabner BA, Johns DG, Bertino JR. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature. 1972;239(5372):395\u20137.","journal-title":"Nature"},{"issue":"9 Suppl.","key":"1135_CR97","first-page":"4773","volume":"67","author":"T Auton","year":"2007","unstructured":"Auton T, Glover J, Melton R, Bastian G, Lovell E. In vitro demonstration that pemetrexed is a good substrate for glucarpidase. Cancer Res. 2007;67(9 Suppl.):4773.","journal-title":"Cancer Res"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01135-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01135-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01135-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T15:50:38Z","timestamp":1673711438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01135-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":97,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1135"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01135-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"21 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by ZonMw, The Netherlands (Grant number: 848016010).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Drs. Nikki de Rouw, Dr. Hieronymus J. Derijks, Prof. Dr. Michel M. van den Heuvel and Dr. Rob ter Heine have nothing to disclose. Dr. Berber Piet reports membership of Advisory Boards of Takeda and Bristol Meyer Squibb and lecturer fees from Astra Zeneca and Pfizer, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Manuscript writing, editing, and revisions: Drs. Nikki de Rouw, Dr. Berber Piet, Dr. Hieronymus J. Derijks, Prof. Dr. Michel M. van den Heuvel, and Dr. Rob ter Heine. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}